|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Nanotherapeutics Announces NanoBUP(TM) Capsule for Treating Opiate Addiction Demonstrated Bioavailability and Safety in Phase Ia Clinical Trial
8/6/2009 10:47:41 AM
ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, Inc., a privately held specialty biopharmaceutical company, announced that NanoBUP™ Oral Buprenorphine / Naloxone Capsule, for treating opiate addiction, demonstrated strong oral absorption in a Phase Ia clinical trial. The 2 x 2mg capsule achieved significant oral bioavailability of 60 to 70 percent, in comparison to sublingual administration of buprenorphine/naloxone at a similar dose, as reported in published scientific reports. NanoBUP™ is a stable, swallowed capsule containing buprenorphine / naloxone developed with the Company’s proprietary NanoDRY® particle delivery system. The product is an immediate release capsule that allows buprenorphine to be absorbed more efficiently from the upper gastrointestinal tract, offering an improved route of administration over currently available formulations.
|
|
|
|
|
|
|
|
|
|
|